Researchers in India have retracted their 2013 case report of a “novel” way to treat a swallowing disorder because, well, the way wasn’t novel at all.
The article, “A novel approach for the treatment of dysphagia lusoria,” was published in the European Journal of Cardio-Thoracic Surgery by a group from the Sri Jayadeva Institute of Cardiovascular Sciences and Research in Bangalore.
Ever wanted to hone your skills as a scientific sleuth? Now’s your chance.
Thanks to the American Society for Biochemistry and Molecular Biology (ASBMB), which is committed to educating authors on best practices in publishing, figure preparation, and reproducibility, we’re presenting the third in a series, Forensics Friday.
Take a look at the image below, and then take our poll. After that, click on the link below to find out the right answer.
Apparently, you can be a little bit pregnant. We’ll explain.
The other day we received an email from a researcher tipping us off to a remarkable admission from a journal in Pakistan about how much (as in, precisely how much) plagiarism it was willing to accept in its pages.
The publication, the Punjab University Journal of Mathematics, had approached the researcher (whom we’re not identifying, at their request) asking them to be a reviewer. When the scientist demurred, the following message arrived:
A former researcher at Boston University (BU) committed research misconduct, according to the U.S. Office of Research Integrity (ORI).
William W. Cruikshank, formerly of BU’s Pulmonary Center, “engaged in research misconduct by knowingly, intentionally, and/or recklessly falsifying and/or fabricating data” in a paper retracted in 2014, in an earlier version of that paper, in a seminar presentation, and in two grant applications submitted to the National Cancer Institute, the ORI reports.
Cruikshank did so by “copying blot band images from unrelated sources, manipulating to disguise their origin, and combining multiple images to generate new figures to falsely represent results using sixty-four (64) such band images” in 16 figures and related text.
Last year, amid concerns for patient safety, the U.S. National Institutes of Health (NIH) suspended seven grants to Duke University following “allegations of research misconduct…and…potential issues concerning clinical research irregularities,” we now know thanks to a letter from NIH to Duke.
On March 30, 2018, The Ohio State University (OSU) released a 75-page report concluding that Ching-Shih Chen, a cancer researcher, had deviated “from the accepted practices of image handling and figure generation and intentionally falsifying data.” The report recommended the retraction of eight papers.
By the end of August of 2018, Chen had had four papers retracted — one in Cancer Research, two in the Journal of Medicinal Chemistry, and one in PLoS ONE.
But it wasn’t until more than a year after the report was released that the other four papers — two from Carcinogenesis, one from Clinical Cancer Research, and one from Molecular Cellular Therapeutics — were retracted, all between April 1 and May 1 of this year.
What took so long? Your guess is as good as ours; none of the editors of those journals responded to our requests for comment.
Ever wanted to hone your skills as a scientific sleuth? Now’s your chance.
Thanks to the American Society for Biochemistry and Molecular Biology (ASBMB), which is committed to educating authors on best practices in publishing, figure preparation, and reproducibility, we’re presenting the second in a series, Forensics Friday.
Take a look at the image below, and then take our poll. After that, click on the link below to find out the right answer.
Retraction Watch readers may have noticed what seems like a growing trend: Co-first authorships. While the move might seem like a way to promote equality, some researchers are worried that it’s having the opposite effect. In response, the Journal of Clinical Investigation (JCI) recently created additional requirements for shared first authorship. We asked Arturo Casadevall, the first author of an editorial describing those changes, to answer a few questions.
Retraction Watch (RW): The title of your editorial, as well as the editorial itself, refers to bias. What kind of bias is of concern when it comes to co-first authors?